Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 5031926, 17 pages
https://doi.org/10.1155/2017/5031926
Research Article

Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway

1Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Clinical Research Institute, Daejeon St. Mary’s Hospital, Daejeon, Republic of Korea

Correspondence should be addressed to Hyeon Seok Hwang; rk.ca.cilohtac@shgnawh

Received 4 December 2016; Accepted 23 February 2017; Published 29 March 2017

Academic Editor: Vladimir Jakovljevic

Copyright © 2017 Yu Ah Hong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplement Figure 1: Paricalcitol protected HK-2 cells against H2O2-induced death via an EP4-dependent pathway. Paricalcitol significantly prevented H2O2-induced cell death. Co-treatment with paricalcitol and AH-23848 restored the cell death to such an extent from H2O2-exposed cells without paricalcitol. Each column represents the mean ± SEM of three independent experiments. *P < 0.05.

  1. Supplementary Material